Ahead of Taaleri's half-year financial report, due on 20 August, we keep our underlying estimates in...
Redeye views the Q2 report as further confirmation of a successful strategy to already arrive at bei...
Q2e: US operations stable, Germany still struggling We expect Ferronordic to report Q2 net sales of ...
Redeye gives its preview on OssDsign’s Q2 2024 report, due on August 20.
Redeye saw a report where sales exceeded our expectations.
Redeye expects Smart Eye's Q2, due 21 August, to show a 42% y/y sales growth and a mere SEK4m EBITDA...
Redeye leaves its initial take on Physitrack’s Q2 figures, which overall was line with our expectati...
Redeye provides its initial comments on the Q2 2024 report from Scandinavian Chemotech, which was mo...
Sales of ~SEK 20m, but with negative margins This afternoon, Bredband2 announced the acquisition of ...
Net sales came in 4% above our forecast, while adjusted EBITDA was 1% below our expectation for Q2.
Redeye updates on G5 following its Q2-result which was somewhat weaker than expected.
Suominen's Q2 earnings fell slightly short of Vara consensus expectations, which leaves some uncerta...
Q2e on 29 Aug, expect a slow quarter before more transactions in H2 We lower '24e-'25e EBIT by 31% a...
Redeye provides a research update following the Q2 report published by Lipum earlier today.
Redeye returns with a positive view on the back of Bredband2’s Q2 2024 report which was in line with...
